News – Page 444 – Endpoints News

J&J plans to cut 64 jobs at New York plant in new year

3 years ago

New industry report suggests UK clinical trial research recruitment is in massive decline

3 years ago

Bristol Myers lines up a date with the FDA to expand the footprint of its $13B heart drug

3 years ago

Gilead presses forward with next-gen CAR-T, inking deal with small synthetic biology startup

3 years ago

Updated: With new $100M investment, a biotech with two approved drugs spins out its manufacturing business

3 years ago

As links to MS deepen, researchers accelerate efforts to develop an Epstein-Barr vaccine

3 years ago

As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine

3 years ago

Immunic reports another trial flop, and execs blame 'confounded' placebo response as shares sink

3 years ago

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

3 years ago

Indegene acquires first healthcare ad agency, picking up physician and consumer marketing expertise

3 years ago

How to avoid false conclusions: FDA finalizes long-awaited guidance on multiple endpoints in clinical trials

3 years ago

Takeda sues Apotex over prospective generic versions of its top leukemia drug

3 years ago

Manufacturing roundup: Hikma, Lilly US manufacturing sites hit with 483s; GAO says HHS should address stockpile risks

3 years ago

Sanofi sells Japanese manufacturing site to CDMO but maintains supply agreement

3 years ago

ICER calls out three drugs from BMS and Lilly in report on unsupported price increases in California

3 years ago

Novartis signs landmark licensing deal to expand access to patented cancer drug

3 years ago

'Hook'ed on KRAS, Roche lines up licensing deal as it pursues Mirati and Amgen

3 years ago

Playboy, digital health, electric vehicles and now cancer drugs: A mountainous SPAC journey

3 years ago

AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech for $255M+

3 years ago

Updated: A New Jersey biotech shuffles C-suite, halts promotion of yeast infection drug and lays off employees

3 years ago

Four months after implementing new PhIII safety protocol, organ transplant biotech reports patient death

3 years ago

Takeda adds one more late-stage treatment to its growing roster of celiac drugs

3 years ago

Charles River cuts the ribbon on former AstraZeneca site in the UK for plasmid manufacturing

3 years ago

AM-Pharma flies white flag on PhIII battle, but they aren't giving up on their kidney drug

3 years ago

First page Previous page 441 442 443444445 446 447 Next page Last page